FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200938257> ?p ?o ?g. }

• W3200938257 endingPage "1319" @default.
• W3200938257 startingPage "1309" @default.
• W3200938257 abstract "Summary Background Infliximab is a chimeric monoclonal antibody against tumour necrosis factor‐alpha for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Recently, a subcutaneous formulation of CT‐P13, an infliximab biosimilar, was approved for clinical use. Aims To characterise CT‐P13 pharmacokinetics (PK) and its clinically relevant determinants after subcutaneous administration through population PK modelling. Methods Data from a two‐part Phase I study with intravenous (5 mg/kg) and variable maintenance subcutaneous dosing of CT‐P13 with frequent PK sampling in patients with CD or UC were used. Population PK analysis was conducted by non‐linear mixed effects modelling. Covariates affecting PK parameters were chosen based on their clinical relevance (effect size of ≥20%) using a full fixed‐effect modelling approach. Results CT‐P13 PK was described by a two‐compartment model with linear elimination. The half‐life in a typical 70 kg patient with serum albumin of 44 g/L was 10.8 days. The typical value for clearance was 0.355 L/d, absorption constant 0.273/d, bioavailability 79.1%, central volume of distribution 3.10 L and peripheral volume of distribution 1.93 L. Clinically relevant covariates affecting clearance were body weight (+43.2% from 70 to 120 kg), the presence of anti‐drug antibodies (+39%) and serum albumin concentration (+30.1% from 44 to 32 g/L). Simulated drug exposure was comparable between routes of administration for patients weighing 50 or 70 kg, but lower with subcutaneous dosing in patients weighing 120 kg. Conclusions This first population PK model for subcutaneous CT‐P13 supports fixed subcutaneous maintenance dosing, although heavy patients had lower cumulative drug exposure." @default.
• W3200938257 created "2021-09-27" @default.
• W3200938257 creator A5021986417 @default.
• W3200938257 creator A5052278532 @default.
• W3200938257 creator A5067266121 @default.
• W3200938257 creator A5069015142 @default.
• W3200938257 creator A5075968197 @default.
• W3200938257 date "2021-09-24" @default.
• W3200938257 modified "2023-10-18" @default.
• W3200938257 title "Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis" @default.
• W3200938257 cites W1516626166 @default.
• W3200938257 cites W1547943993 @default.
• W3200938257 cites W1759963899 @default.
• W3200938257 cites W1940516511 @default.
• W3200938257 cites W1978383327 @default.
• W3200938257 cites W2006783956 @default.
• W3200938257 cites W2015186160 @default.
• W3200938257 cites W2018956144 @default.
• W3200938257 cites W2039232895 @default.
• W3200938257 cites W2044160586 @default.
• W3200938257 cites W2056427920 @default.
• W3200938257 cites W2063138494 @default.
• W3200938257 cites W2064877889 @default.
• W3200938257 cites W2074900601 @default.
• W3200938257 cites W2076523377 @default.
• W3200938257 cites W2091573816 @default.
• W3200938257 cites W2111354448 @default.
• W3200938257 cites W2115092402 @default.
• W3200938257 cites W2618875195 @default.
• W3200938257 cites W2744879509 @default.
• W3200938257 cites W2806704569 @default.
• W3200938257 cites W2883052264 @default.
• W3200938257 cites W2904090159 @default.
• W3200938257 cites W2918732160 @default.
• W3200938257 cites W2923675504 @default.
• W3200938257 cites W2978824500 @default.
• W3200938257 cites W3001350765 @default.
• W3200938257 cites W3002318915 @default.
• W3200938257 cites W3003887243 @default.
• W3200938257 cites W3070061292 @default.
• W3200938257 cites W3118942260 @default.
• W3200938257 cites W3119729028 @default.
• W3200938257 cites W3134678138 @default.
• W3200938257 cites W3141994374 @default.
• W3200938257 cites W3200938257 @default.
• W3200938257 cites W4211138554 @default.
• W3200938257 cites W4242880987 @default.
• W3200938257 doi "https://doi.org/10.1111/apt.16609" @default.
• W3200938257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34559426" @default.
• W3200938257 hasPublicationYear "2021" @default.
• W3200938257 type Work @default.
• W3200938257 sameAs 3200938257 @default.
• W3200938257 citedByCount "16" @default.
• W3200938257 countsByYear W32009382572021 @default.
• W3200938257 countsByYear W32009382572022 @default.
• W3200938257 countsByYear W32009382572023 @default.
• W3200938257 crossrefType "journal-article" @default.
• W3200938257 hasAuthorship W3200938257A5021986417 @default.
• W3200938257 hasAuthorship W3200938257A5052278532 @default.
• W3200938257 hasAuthorship W3200938257A5067266121 @default.
• W3200938257 hasAuthorship W3200938257A5069015142 @default.
• W3200938257 hasAuthorship W3200938257A5075968197 @default.
• W3200938257 hasBestOaLocation W32009382571 @default.
• W3200938257 hasConcept C112705442 @default.
• W3200938257 hasConcept C126322002 @default.
• W3200938257 hasConcept C139254425 @default.
• W3200938257 hasConcept C17991360 @default.
• W3200938257 hasConcept C2776390293 @default.
• W3200938257 hasConcept C2777138892 @default.
• W3200938257 hasConcept C2777288759 @default.
• W3200938257 hasConcept C2778260677 @default.
• W3200938257 hasConcept C2779134260 @default.
• W3200938257 hasConcept C2779280984 @default.
• W3200938257 hasConcept C2780479503 @default.
• W3200938257 hasConcept C2908647359 @default.
• W3200938257 hasConcept C71924100 @default.
• W3200938257 hasConcept C90924648 @default.
• W3200938257 hasConcept C98274493 @default.
• W3200938257 hasConcept C99454951 @default.
• W3200938257 hasConceptScore W3200938257C112705442 @default.
• W3200938257 hasConceptScore W3200938257C126322002 @default.
• W3200938257 hasConceptScore W3200938257C139254425 @default.
• W3200938257 hasConceptScore W3200938257C17991360 @default.
• W3200938257 hasConceptScore W3200938257C2776390293 @default.
• W3200938257 hasConceptScore W3200938257C2777138892 @default.
• W3200938257 hasConceptScore W3200938257C2777288759 @default.
• W3200938257 hasConceptScore W3200938257C2778260677 @default.
• W3200938257 hasConceptScore W3200938257C2779134260 @default.
• W3200938257 hasConceptScore W3200938257C2779280984 @default.
• W3200938257 hasConceptScore W3200938257C2780479503 @default.
• W3200938257 hasConceptScore W3200938257C2908647359 @default.
• W3200938257 hasConceptScore W3200938257C71924100 @default.
• W3200938257 hasConceptScore W3200938257C90924648 @default.
• W3200938257 hasConceptScore W3200938257C98274493 @default.
• W3200938257 hasConceptScore W3200938257C99454951 @default.
• W3200938257 hasIssue "10" @default.
• W3200938257 hasLocation W32009382571 @default.
• W3200938257 hasLocation W32009382572 @default.

• next